Business highlights in Q1 2022

  • On January 20th the initiation of dosing in the IPTN2021 program Phase 1 to assess pain reducing effects in healthy volunteers was announced.
  • On March 22nd it was announced that the inclusion of test subjects in the IPTN2021 Phase 1 study had been completed.

Business highlights after this reporting period

  • On April 5th the Company announced that it has signed an option agreement for a Phase 2/3 ready drug asset for an undisclosed pain indication.
  • On April 13th the Board of Directors proposed a directed share issue and fully guaranteed rights issue of a total of approximately SEK 61 million to finance its clinical programs into the beginning of 2024.

Financial Highlights

First Quarter (2022-01-01 – 2022-03-31)
Net revenues were TDKK 0 (0)
Operating loss, EBIT was TDKK -15 075 (-1 792)
Earnings per share was DKK –0.35 (-0.07)
Earnings per share, fully diluted, was DKK –0.31 (-0.06)
Cash: TDKK 26,352 (34,346)
Solidity: 65% (92%)

Solidity: equity divided by assets.

The Board of Directors have decided that future interim reports will be published in English only.

Link to the full report